Low level of plasma VEGF-A and C allele of -2578*C/A polymorphism in the VEGF-A gene are risk factors of diabetic foot ulcer in Javanese ethnic

Ika Rahayu1,2*, Hemi Sinorita3, Kris Herawan Timotius1,2, Ahmad Hamim Sadewa4
1 Department of Biochemistry, Faculty of Medicine, Universitas Kristen Krida Wacana, Jakarta, 2 Research Center for Jamu and Herbal Medicine, Universitas Kristen Krida Wacana, Jakarta, 3 Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada / Dr.Sardjito General Hospital, Yogyakarta, 4 Department of Biochemistry, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

ABSTRACT

Diabetes mellitus (DM) is caused by abnormal insulin secretion, impaired insulin action, or both. Approximately 12-25% of type 2 diabetes mellitus (T2DM) patients will develop diabetic foot ulcers (DFU). Vascular endothelial growth factor (VEGF) is a group of platelet-derived growth factors (PDGF) which have a potential role in angiogenesis. Low levels of VEGF-A can cause insufficient angiogenesis leading to wound healing inhibition. The 2578*C/A polymorphism of VEGF-A gene has been reported as a candidate marker for the DFU development. However, the variant role in the development of DFU in Javanese ethnic needs to be clarified. This study was conducted to compare VEGF-A levels and the -2578*C/A polymorphism of the VEGF gene among diabetic patients with and without DFU in Javanese ethnic. In this case-control study, the T2DM individuals with DFU as case group (n=19) and without DFU as control group (n=41) were recruited. The VEGF-A levels were determined by ELISA. The ARMS-PCR technique was applied to investigate the presence of -2578*C/A polymorphism of the VEGF gene. Data were analyzed with independent t, Mann-Whitney, Chi-square, and Kruskal-Wallis tests with significance level of p<0.05. The median of plasma VEGF-A level was significantly different between case and control groups (p=0.001). The genotype frequency of -2578*C/A polymorphism of VEGF gene was no difference between case and control groups. However, individuals with C allele have a higher risk factor to develop DFU than A allele (CC+CA vs AA; p=0.042; OR=2.5). The plasma VEGF-A levels were lower in T2DM subjects with DFU than those without DFU. In conclusion, individuals with C allele of -2578*C/A polymorphism of VEGF gene are more susceptible to have DFU than individuals with A allele in Javanese ethnic with T2DM.

Keywords: diabetic foot ulcers; VEGF-A; -2578*C/A polymorphism of VEGF-A gene; type 2 diabetes mellitus;
DMT2 with DFU as the case group (n=19) and those without DFU as the control (n=41). The VEGF-A levels were determined using the ELISA method. The ARMS-PCR technique was used to detect the -2578*C/A polymorphism of the VEGF gene. Data analysis was performed using independent t-tests, Mann-Whitney, Chi-square, and Kruskal-Wallis tests with a significance level of p < 0.05. The median VEGF-A plasma level was found to be significantly different between the case and control groups (p=0.001). The frequency of the genotype -2578*C/A of the VEGF gene did not significantly differ between the case and control groups. However, patients carrying allele C had a higher risk of developing DFU compared to those carrying allele A (CC+CA vs AA; p=0.042; OR=2.5). Patients with DMT2 and DFU had lower VEGF-A plasma levels compared to those without DFU. It can be concluded that patients carrying allele C -2578*C/A of the VEGF gene are more susceptible to developing DFU compared to those carrying allele A among Javanese DMT2 patients.

INTRODUCTION

Diabetic foot ulcer (DFU) is a common infection among patients with diabetes mellitus (DM) due to tissue invasion accompanied by microorganism's proliferation leading to tissue damage with or without an inflammatory response of the host cell. Approximately 12-25% of diabetic patients will develop DFU. While its prevalence is low in Western countries, India is the country with the highest rate of amputation for DFU in Asia. It was reported that 3.6% of DM patients in India developed DFU in 1994. In Indonesia, while the exact number of DFU is unknown, the population of DM patients has been increasing and was ranked 7th in the world with approximately 10 million cases in 2015. The diabetes complications such as DFU are also predicted to be higher with the rising of DM's annual prevalence which subsequently reduces the quality of life of patients. Poor glycemic and hygienic control of diabetic patients play an important role in the increasing chance of skin infection and the cell's reduced responsiveness against microorganisms.

Angiogenesis plays an important role in the wound healing process. Vascular endothelial growth factor-A (also referred to as VEGF) is a group of platelet-derived growth factors (PDGF) which has a potential role in angiogenesis. Wilgus et al. reported the important role of VEGF-A in wound healing. Increased levels of VEGF-A are related to the alteration of the scar and the recovery of fetus skin fibrosis, also reduction of scars, and improved collagen quality. Vascular endothelial growth factor improved wound healing in diabetic wounds. The VEGF also induced chemotaxis and angiogenesis. Angiogenesis inhibition would inhibit wound healing.

The -2578*C/A polymorphism of the VEGF-A gene is one of the polymorphisms located in the 5'-untranslated promoter region. Marsh et al. reported that this polymorphism reduces mRNA expression, which influences the tissue wound healing process. Amoli et al. investigated -2578*C/A VEGF gene variations and found that this variant was the candidate risk factor of DFU development in an Iranian population. Shahbazi et al. reported that -2578*C/A polymorphism of the VEGF gene leads to diminished VEGF level.

This study was conducted to compare plasma VEGF levels and to investigate the -2578*C/A polymorphism of the VEGF-A gene among diabetic patients with and without DFU in a Javanese ethnic.

MATERIALS AND METHODS

Subjects

It was a case-control study. The subjects were divided into two groups. The case group was T2DM patients with DFU, and the control group was T2DM patients without DFU. Subjects were...
recruited from Dr. Sardjito General Hospital, Yogyakarta, Indonesia.

The physical examination was used to determine the DFU status. The Wagner Grading System was performed for foot ulcer assessing, and grading. The anamneses and family pedigree were used to confirm the ethnic status. The Javanese men or women aged 30-65 years old who have been diagnosed with T2DM at least 5 years and DFU were recruited as the case group. The patients with the same previous characteristics but without DFU were included as the control group. The patient informed consent forms were signed by all patients which were included in this study. Five mL of venous blood was collected in EDTA tubes and examined for VEGF-A plasma level and genotyping of VEGF-A gene. Ethical clearance of this study was obtained from the Medical and Health Research Ethic Committee, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta.

**Enzyme-linked immunosorbent assay (ELISA)**

The plasma VEGF-A levels were measured by enzyme-linked immunosorbent assay (ELISA) using Abcam® Kit according to the manufacturer’s instruction.

**DNA Isolation**

DNA isolations were carried out using Tianamp blood DNA kit (Tiangen®). The DNA yields were stored at -20°C.

**Tetra-primer amplification refractory mutation system-polymerase chain reaction (ARMS-PCR)**

The ARMS-PCR technique described by Amoli et al.\(^1\) was performed to determine -2578*C/A polymorphism of the VEGF-A gene and used five primers (TABLE 1).\(^1\) Three types of master mix were made based on the type of primer; the first reaction of master mix contained generic forward primer and antisense primer C, the second reaction of master mix contained generic forward primer and antisense primer A, and the third reaction of master mix contained the primer of beta actin. Two µL of DNA solution was added to the 4.2 µL of master mix. As much as 13.8 µL nuclease-free water was added to the solution.

Twenty µL of mixtures were amplified on the thermocycler (ESCO®). The hot-start step was carried out for 10 min at 95°C. The following 35 cycles of 1 min for denaturation at 95°C, 1 min for annealing at 60°C, 1 min for elongation at 72°C were performed. Final elongation was carried out for 7 min at 72°C. The amplicons were electrophoresed in 2% of agarose gel and visualized under UV illumination. Genotypes were identified by the presence or absence of the amplified target sequence. The expected PCR product was 223 bp for VEGF-A and 315 bp for beta actin.

| Primer Sequence | Primer Sequence |
|-----------------|-----------------|
| 5’-TTAGGACACCATAACCGATGG-3’ | 5’-TTAGGACACCATAACCGATGG-3’ |
| 5’-TCTGATTATCCACCAGATCG-3’ | 5’-TCTGATTATCCACCAGATCT-3’ |
| 5’-CTTCCTTCTGAGGATGG-3’ | 5’-CTTCCTTCTGAGGATGG-3’ |
| 5’-TGGAGGGGCGGACTGTCA-3’ | 5’-TGGAGGGGCGGACTGTCA-3’ |

TABLE 1. List of primers used in this experiment according to Amoli et al.\(^1\)
Statistical analysis

Characteristics of the subjects were analyzed by Independent t-test or Mann-Whitney test. Genotype and allele frequencies were analyzed by the Chi-square test. The distribution of plasma VEGF-A levels in individuals with T2DM and without DFU was analyzed by Mann-Whitney test. The value was considered significant if the p-value is less than 0.05.

RESULTS

Clinical characteristic of T2DM patients

In this study, the 60 T2DM patients were divided into two different groups. The 19 patients with DFU were subgrouped as the case group, while the 41 patients without DFU (NDFU) were subgrouped as the control group. TABLE 2 shows data of the clinical characteristics of the patients obtained from medical records. There was no significant difference in clinical characteristics between case and control subjects (p>0.05).

Plasma VEGF-A level related to diabetic foot ulcer incidence

The median of VEGF-A levels in the case and control subjects are shown in TABLE 3. The VEGF-A level of case subjects was significantly lower than control subjects (p = 0.001).

### TABLE 2. Clinical characteristics of patients

| Variable                  | DFU (n=19) | NDFU (n=41) | p   |
|---------------------------|------------|-------------|-----|
| **Sex**                   |            |             |     |
| Men                       | 6 (%)      | 16 (%)      | 0.581|
| Women                     | 13 (%)     | 25 (%)      |     |
| **Age (year)**            | 54.8±6.7   | 55.8±6.2    | 0.597|
| **BMI (kg/m²)**           | 22.9 (16.8-24.9) | 22.6 (16.1-24.8) | 0.709*|
| **Blood pressure (mmHg)** |            |             |     |
| Systole                   | 128.6±20.9 | 127.4±23.7  | 0.770*|
| Diastole                  | 75.5±14.8  | 77.7±13.1   | 0.554|
| **Total cholesterol (mg/dL)** | 202.8±62.9 | 202.4±40.4 | 0.824*|
| **Fasting blood glucose (mg/dL)** | 164.3±54.6 | 189.1±78.6 | 0.271*|

Data are reported as mean±SD or median (minimum-maximum); *Man-Whitney test; #Independent t-test.

### TABLE 3. The VEGF-A level of case (DFU) and control (NDFU) groups

| Variable        | DFU    | Non DFU | p   |
|-----------------|--------|---------|-----|
| VEGF-A level(pg/mL) | 225.9  | 1367.0  | 0.001*|
|                 | (27.2-2102.7) | (19.5-4908.7) |

Data are reported as median (minimum-maximum); *Mann-Whitney test.
Genotype and allele frequencies distribution of the -2578*C/A polymorphism in the VEGF-A gene

Three genotypes were found in the control group (CC, CA, and AA), while two genotypes were found in the case group (CC and CA) (FIGURE 1). The distributions of genotypes and alleles were statistically analyzed using Chi-square test (TABLE 4). Chi-square analysis showed that differences of genotype and allele frequencies of -2578*C/A VEGF-A in the case and control subjects were not statistically significant (p = 0.289 for the genotype frequencies and p = 0.653 for allele frequencies). But the major allele (C allele) conferred a risk factor for the DFU development (OR = 2.5; p = 0.042).

![Image of gel electrophoresis](image.png)

**FIGURE 1.** Genotype result of -2578 * C/A VEGF-A gene polymorphism. M = marker. B = beta actin. CC = wild-type. CA = mutant heterozygote. AA = mutant homozygote. Z3=AA, Z29=CC, Z21=CA, Z37=CA.

**TABLE 4.** Distribution of genotype and allele VEGF-A -2578 *C/A in case (DFU) and control (Non DFU) subject

| Variable | DFU (n=19) | Non DFU (n=41) | p      |
|----------|------------|----------------|--------|
| Genotype |            |                |        |
| • AA     | 0          | 2 (4.9)        |        |
| • CA     | 16 (84.2)  | 27 (65.9)      | 0.289* |
| • CC     | 3 (15.8)   | 12 (29.3)      |        |
| Allele   |            |                |        |
| • A      | 16 (42.1)  | 31 (37.8)      | 0.653* |
| • C      | 22 (57.9)  | 51 (62.2)      |        |
| • CC + CA| 19         | 29             | 0.042* |
| • AA     | 0          | 2              |        |

*Chi square test; * Yates correction
Association between VEGF-A plasma level with -2578*C/A VEGF-A polymorphism

The relationship of VEGF-A profile and VEGF-A polymorphisms are shown in TABLE 5. Results showed that VEGF-A levels in the AA genotype are higher than CC and CA genotypes. However, the VEGF-A levels were not significantly different between that genotype groups after statistical analysis (p = 0.138).

| Variable | T2DM (DFU and Non DFU) | p     |
|----------|------------------------|-------|
|          | CC + CA                | AA    |       |
| VEGF-A level (pg/mL) | 1120.5 (19.5-4908.7) | 2186.8 (1709.9-2663.7) | 0.138* |

Data are reported as median (minimum-maximum); *Mann-Whitney test

DISCUSSION

This study confirmed that a low VEGF-A level leads to poor angiogenesis, and is a risk factor for the development of DFU. The VEGF-A levels of the control group (non-DFU) are significantly higher than the case group (DFU) (p = 0.001). In previous study, the VEGF-A plasma level is associated with the development of diabetic retinopathy and nephropathy. High levels of VEGF-A are a risk factor for diabetic retinopathy. In contrast, our results showed that low levels of VEGF-A act as a risk factor for DFU. Hoong et al.\textsuperscript{13} examined the VEGF-A levels in T2DM and found that the levels were higher than in healthy subjects. The median VEGF-A level of healthy subjects was 90 (10-230) pg/mL, whereas the median VEGF-A level in the T2DM patients was 180 (120-420) pg/mL.\textsuperscript{13} Another study found that VEGF-A levels of diabetic patients were increased relative to healthy controls (928.9±443.2 and 491.7±275.5 pg/mL, respectively).\textsuperscript{14} These results support the previous idea that levels of VEGF-A should be maintained within normal ranges to prevent the progression of complications in diabetic patients.

In the aim to investigate the association between VEGF polymorphism and VEGF level, we genotyped subjects for -2578C*/A polymorphism. The results showed the presence of three genotypes of CC, CA, and AA. Statistical analysis revealed that the genotype and allele frequencies of -2578*C/A polymorphisms of the VEGF-A gene are not significantly different between case and control subjects (TABLE 4). In addition, the level of VEGF-A was compared among each genotype to determine the relationship of -2578*C/A polymorphisms. The VEGF-A levels in AA genotype patients are higher than those of CC and CA genotype patients, but the difference was not significant statistically (p = 0.138). This result is similar to Habboubi et al.\textsuperscript{15} who also reported that VEGF-A level of CC, CA, and AA genotype carriers were not significantly different from healthy subjects. But this finding is contrary to the research that was reported by Guerzoni et al.\textsuperscript{16} who found that VEGF-A expression was diminished due to the AA genotype at -2578 VEGF-A. Apparently, the production of VEGF-A is influenced by both genetic and non-genetic determinants.\textsuperscript{17,18} Since many factors contribute to the VEGF-A expression, a direct association between -2578*C/A polymorphism and plasma VEGF-A level in patients with T2DM is still in debate.\textsuperscript{19}

However, when the genotypes are divided based on risk alleles, the CA and CC groups are more susceptible to DFU compared to the AA (OR = 2.5; p =
This means that the probability of patients who carry CC and CA genotypes developing DFU is 71.4% higher than the AA genotype. Since the C allele is a common one, many patients with T2DM are actually prone to DFU in the Indonesian Javanese population. The mechanism by which the C allele reduces VEGF-A expression is unknown. The -2578*C/A polymorphism of the VEGF-A gene is one of the five promoter polymorphisms present in the 5’translated region (UTR), which has been identified so far.8 Several transcription factors bind to this region and polymorphisms located here cause alteration of VEGF-A expression. It is speculated that one C allele is not strong enough to drive low VEGF-A production since the interaction of other transcription factors may occur.20,21

High blood glucose levels affect the circulating of angiogenic factors that contribute to the inhibition of wound healing. Natarajan et al.22 reported that hyperglycemia was a major determinant to the elevating of VEGF-A expression. Metabolic balance disorders, such as diabetes can elevate the oxidation of sorbitol to fructose and cause reduction of NAD+ to NADH. Once the redox balance is disturbed, it would elevate superoxides that induce VEGF production leading to endothelial dysfunction.23 Other variables that might be considered in the development of DFU are proinflammatory mediators which increase in patients with T2DM and induce inflammation continuously. Mild inflammation causes impaired cellular defense mechanisms because of hyperglycemia. It has been shown that there is a strong relationship between the development of DFU with proteolytic environment.24 Impaired wound healing in patients with DM is also caused by a reduction of angiogenesis ability. Research shows that the number of growth factors has decreased in diabetic wounds caused by proinflammatory mediators.25 The release of VEGF, PDGF, and TGF-β from platelets, monocytes, and fibroblasts induces angiogenesis that is important in the wound healing process.26 If these growth-factors were reduced, insufficient angiogenesis will occur.

Most diabetic patients undergo peripheral polyneuropathy, as the most common form of diabetic neuropathy.27 Diabetic neuropathy is another risk factor of developing foot ulcers since patients will have a loss of sensation because of nerve damage.28 VEGF-A is not the only factor that affects the wound healing of DFU. Pathophysiology of DM and impaired wound healing are very complex. Diabetic patients undergo an abnormal development process of wound healing compared with the normal subjects. It is caused by the association of diabetes and microangiopathy and also their impaired immune system.29,30 Therefore, research on these topics are very important to understand the pathophysiology of DFU and to overcome this problem in Indonesia. One limitation of this research is the small sample size. We had difficulty recruiting samples because some patients with DFU had comorbid complications with other diseases that affect the angiogenesis process.

CONCLUSION

The plasma VEGF-A levels are lower in T2DM subjects with DFU than those without DFU. Individuals with C allele of -2578*C/A polymorphism of the VEGF gene are more susceptible to have DFU than individuals with A allele in Javanese ethnic with T2DM.

ACKNOWLEDGEMENT

This study is a part of the master thesis that supported by a grant from the Ministry of National Education, Indonesia.
REFERENCES

1. Anonim. Management of diabetic foot infections. Med Mal infect 2007; 37(1):14-25.
2. Cavanagh PR, Lipsky BA, Bradbory AW, Botek G. Treatment for diabetic foot ulcers. Lancet 2005; 366(9498):1725-35. https://doi.org/10.1016/S0140-6736(05)67699-4
3. Pendsey S. Epidemiologiaspects of diabetic foot. Int J Diab Dev Countries 1994; 14:37-8.
4. International Diabetes Federation. IDF diabetes atlas 7th ed. 2015. www.idf.org/diabetesatlas
5. Hena J, Growther L. Studies on bacterial infections of diabetic foot ulcer. Afr J Clin Expert Microbiol 2010; 11(3):146-9.
6. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Investig DermatolSymp Proc 2000; 5(1):40-6. https://doi.org/10.1046/j.1087-0024.2000.00014.x
7. Wilgus TA, DiPietro LA. Complex roles for VEGF in dermal wound healing. J Invest Dermatol 2012; 132(2):493-4. https://doi.org/10.1038/jid.2011.343
8. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphism in the promoter and 5’UTR regions of human vascular endothelial growth factor gene. 1999. In: Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13(1):260-4.
9. Marsh S, Nakhoul FM, Skorecki K, Rubin A, Miller BP, Leibu R, et al. Hypoxic induction of vascular endothelial growth factor is marked decreased in diabetic individuals who do not develop retinopathy. Diabetes Care 2000; 23(9):1375-80. https://doi.org/10.2337/diacare.23.9.1375
10. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154(2):355-63. https://doi.org/10.1016/S0002-9440(10)65282-0
11. Amoli MM, Hasani-Ranjbar S, Roohipour N, Sayahpour FA, Amiri P, Zahedi P et al. VEGF gene polymorphism association with diabetic foot ulcer. Diabetes Res Clin Pract 2011; 93(2):215-9. https://doi.org/10.1016/j.diabres.2011.04.016
12. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13(1):260-4.
13. Hoong SL, Blann AD, Aun YC, Freestone B, Lip GYH. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes. Diabetes Care 2004; 27(12):2918-24. https://doi.org/10.2337/diacare.27.12.2918
14. Kusumanto YH, Meijer C, Dam W, Mulder NH, Hospers GAP. Circulating vascular endothelial growth factor (VEGF) levels in advanced stage cancer patient compared to normal controls and diabetes mellitus patients with critical ischemia. Drug Target Insight 2007; 2:105-9.
15. Al-Habboubi H, Sater MS, Almawi AW, Al-Khateeb GM, Almawi WY. Contribution of VEGF polymorphism to variation in VEGF serum level in a healthy population. Eur Cytokine Netw 2011; 22(3):154-8. https://doi.org/10.1684/ecn.2011.0289
16. Guerzoni AR, Biselli PM, de Godoy MF, Souza DRS, Haddad R, Eberlin
MN et al. Homocysteine and MTHFR and VEGF gene polymorphism: Impact on coronary artery disease. Aq Bras Cardiol 2009; 92(4):249-54. https://doi.org/10.1590/s0066-782x2009000400003
17. Ruggiero D, Dalmasso C, Nutile T, Sorice R, Dionisi L, Aversano M et al. Genetic of VEGF serum variation in human isolated populations of Cilento: Importance of VEGF polymorphism. PloS One 2011; 6(2):e16982. https://doi.org/10.1371/journal.pone.0016982
18. Habibi I, Sfar I, Chebil A, Kort F, Bouraoui R, Jendoubi-Ayed S et al. Vascular endothelial growth factor genetic polymorphism and susceptibility to age-related macular degeneration in Tunisian population. Biomarker Res 2014; 2:15. https://doi.org/10.1186/2050-7771-2-15
19. Freathy RM, Weedon MN, Shields B, Hitman GA, Walker M, McCarthy MI et al. Functional variation in VEGF is not associated with type 2 diabetes in a United Kingdom caucasian population. JOP 2006; 7(3):295-302.
20. Fukumura D, Xavier R, Sugiura T, Yi C, Eun-Chung P, Naifang L et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94(6):715-25. https://doi.org/10.1016/S0092-8674(00)81731-6
21. Bhanooori M, Babu KA, Reddy NGP, Rao KL, Zondervan K, Deenadayal M et al. The vascular endothelial growth factor (VEGF) 1405G>C 50-untranslated region polymorphism and increased risk of endometriosis in South Indian women: a case control study. Hum Reprod 2005; 20(7):1844-9. https://doi.org/10.1093/humrep/deh852
22. Natarajan R, Bai W, Lanting L, Gonzales, Nadler J. Effect of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am J Physiol 1997; 273(35):H2224-31. https://doi.org/10.1152/ajpheart.1997.273.5.H2224
23. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC et al. Vascular endothelial growth factor induced by elevated glucose level in rats is mediated by vascular endothelial growth factor. J clin Invest 1997; 99(9):2192-022. https://doi.org/10.1172/JCI119392
24. Tellechea A, Leal E, Veves A, Carvalho E. Inflammatory and angiogenic abnormalities in diabetic wound healing: Role of neuropeptides and therapeutic perspectives. Circ Vasc J 2010; 3:43-55. https://doi.org/10.2174/18743.826010.03010043
25. Brem H, Kodra A, Golinko MS, Entero H, Stojadinovic O, Wang VM et al. Mechanism of sustained release of vascular endothelial growth factor in accelerating experimental diabetic healing. J Invest Dermatol 2009; 129(9):2275-87. https://doi.org/10.1038/jid.2009.26
26. Li JJ, Huang YQ, Basch R, Karpatkin S. Thrombin induces the release of angiopoietin-1 from platelets.2001. In: Tellechea A, Leal E, Veves A, Carvalho E. Inflammatory and angiogenic abnormalities in diabetic wound healing: Role of neuropeptides and therapeutic perspectives. Circ Vasc J 2010; 3:43-55.
27. Veves A, King GL. Can VEGF reverse diabetic neuropathy in human subjects? J Clin Invest 2001; 107(10):1215-8. https://doi.org/10.1172/JCI13038
28. Rodrigues J, Mitta N. Diabetic foot and gangrene. 2011. In: Vitin A. (Ed). Gangrene-current concept and management options, pp 121–144. Available from: URL: http://www.intechopen.com.
29. Falanga V. Wound healing and its impairment in the diabetic foot.
30. Galkowska H, Olszewski WL, Wojewodzka U, Rosinski G, Karnafel W. Neurogenic factors in the impaired healing of diabetic foot ulcer. J Surg Res 2006; 134(2):252-8. https://doi.org/10.1016/j.jss.2006.02.006